What is PNC 27 | 5MG & 10MG

PNC 27 | 5MG & 10MG is a synthetic, membrane-active anti-cancer peptide studied in research for its highly selective ability to induce necrosis in solid tumor cells. It is intended exclusively for research use.

Regarding its chemical identity, PNC has a molecular formula of C188H293N49O46S and a molecular weight of 4031.7 g/mol. Its reported canonical sequence is Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Arg-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include PNC.

Product for research use.

Mechanism of action of PNC

PNC 27 contains a p53-derived amino acid sequence attached to a penetratin (membrane-translocating) sequence. It binds specifically to the HDM-2 protein, which is heavily overexpressed on the membranes of cancer cells. This binding causes rapid pore formation and lethal cell membrane lysis (necrosis) in tumor cells, while leaving healthy cells entirely unharmed.

Pharmacokinetics and pharmacodynamics of PNC

As a large, complex peptide, it must be administered systemically to reach tumor sites. It has a relatively short half-life and relies on rapid, direct physical interaction with tumor cell membranes to exert its cytotoxic effects.

Scientific evidence on PNC

The available evidence on PNC is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in in vitro and in vivo models of highly aggressive solid tumors, including melanoma, breast cancer, and pancreatic cancer. Preclinical evidence shows complete eradication of certain tumor types without any observable toxicity to surrounding healthy tissue.

PNC applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

PNC protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for PNC, so no trial schemes or quantities are specified.

The presentations of this product (5MG & 10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of PNC

As a general guideline for laboratory handling, lyophilized peptides such as PNC are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 5MG & 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

PNC Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented PNC security profile

The documented safety information in open sources for PNC is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

PNC 27 exhibits remarkable theoretical safety because its target (membrane-bound HDM-2) is practically absent in healthy cells. It does not cause the systemic immunosuppression, hair loss, or gastrointestinal damage associated with traditional chemotherapy.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

PNC in a comparative context

Unlike traditional chemotherapy, which poisons all rapidly dividing cells, PNC 27 is a targeted, physical destroyer of cancer cell membranes. Unlike LL-37 (which targets bacterial membranes), PNC 27 specifically seeks out the HDM-2 protein marker on mammalian tumors.

History and development of PNC

Developed by researchers at the State University of New York (SUNY) who discovered that the p53 tumor suppressor protein could be engineered into a targeted “smart bomb” that physically destroys cancer cells from the outside in.